Initial Testing (Stage 1) of the Curaxin CBL0137 by the Pediatric Preclinical Testing Program

BACKGROUND: CBL0137 is a novel drug that modulates FACT (Facilitates Chromatin Transcription), resulting in simultaneous Nuclear factor-κB suppression, Heat shock factor 1 suppression and p53 activation. CBL0137 has demonstrated antitumor effects in animal models of several adult cancers and neurobl...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Pediatr Blood Cancer
Hlavní autoři: Lock, Richard, Carol, Hernan, Maris, John M., Kolb, E. Anders, Gorlick, Richard, Reynolds, C. Patrick, Kang, Min H., Keir, Stephen T., Wu, Jianrong, Purmal, Andrei, Gudkov, Andrei, Kurmashev, Dias, Kurmasheva, Raushan T., Houghton, Peter J., Smith, Malcolm A.
Médium: Artigo
Jazyk:Inglês
Vydáno: 2016
Témata:
Article
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC5587189/
https://ncbi.nlm.nih.gov/pubmed/27650817
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/pbc.26263
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky